ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler
DERLEMELER
SARS-COV-2: Çeşitli Belirtiler Hakkında Güncel Bir Derleme
SARS-COV-2: A Current Update About Miscellaneous Symptoms
Received Date : 24 Feb 2021
Accepted Date : 27 Jun 2021
Available Online : 06 Jul 2021
Özet PDF Benzer Makaleler
Tuba Tülay KOCAa, Saime SAĞIROĞLUb
aDepartment of Physical Medicine and Rehabilitation, Sütçü İmam University Faculty of Medicine, Kahramanmaraş, TURKEY bDepartment of Otorhinolaryngology, Sütçü İmam University Faculty of Medicine, Kahramanmaraş, TURKEY
Doi: 10.31609/jpmrs.2021-82578 - Makale Dili: EN
J PMR Sci. 2021;24(3):294-8
ÖZET
Şiddetli akut solunum sendromu-koronavirüs-2 [severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)] partikülü, genetik zemine bağlı olarak konakta farklı klinik yanıtlara neden olur ve iyileşmeden sonra uzun süreli semptomlar gelişebilir. Günümüzün bilgisiyle, SARS-CoV-2 enfeksiyonunu bir otoimmün viral vaskülopati kliniğinin nedeni olarak tanımlayabiliriz. Mevcut bilgilerimizle hangi hastaların şiddetli veya uzun süreli hastalık geliştireceği net değildir. Kronik ağrı, yorgunluk, sarkopeni, vaskülopati, otoimmün bozukluklar, artrit ve santral sensitizasyon gibi SARS-CoV-2 ile ilişkili semptomlara neden olan birçok farklı patofizyolojik mekanizma vardır. SARS-CoV- 2’nin birçok hayati organda mikrotromboz ve endotel disfonksiyonunun sonucu immün yanıt ve yaşamı tehdit eden durumlara neden olduğunu artık biliyoruz. Ayrıca konakta bir immün yanıtı tetikler. Bu immün reaksiyon, uzun vadede otoimmün hastalıkları tetikleyebilir. Bu derlemede, sistemik komplikasyonların yanı sıra özellikle bir fiziyatrist bakış açısından virüsün neden olduğu çeşitli semptomlara odaklandık.
Anahtar Kelimeler: SARS-COV-2; kronik ağrı; sarkopeni; artrit; nörolojik komplikasyonlar
ABSTRACT
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) particle causes different clinical responses in the host depending on the genetic background and prolonged symptoms may develop after recovery. With today's knowledge, we may describe SARS-CoV-2 infection the cause of an autoimmune viral vasculopathy clinic. With our current information, it is not clear which patients will develop severe or prolonged disease. There are many different pathophysiological mechanisms that cause coronavirus disease-2019 related symptoms like chronic pain, fatigue, sarcopenia, vasculopathy, autoimmun disorders, arthritis and central sensitization etc.We now know that SARS-CoV-2 causes immune response and life-threatening conditions as a result of microthrombosis and endothelial dysfunction in many vital organs. Also it triggers an immune response in the host. This immun reaction may trigger autoimmune diseases in the long term. In this review, we especially focused on miscellaneous symptoms caused by virus, from the perspective of a physiatrist, besides systemic complications.
Keywords: SARS-COV-2; chronic pain; sarcopenia; arthritis; neurologic complications
REFERENCES
  1. Bohn MK, Hall A, Sepiashvili L, et al. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020;35:288-301. [Crossref]  [PubMed]  [PMC] 
  2. Marinangeli F, Giarratano A, Petrini F. Chronic Pain and COVID-19: pathophysiological, clinical and organizational issues. Minerva Anestesiol. 2020. [Crossref]  [PubMed] 
  3. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020;125:436-40. [Crossref]  [PubMed]  [PMC] 
  4. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-32. [Crossref]  [PubMed]  [PMC] 
  5. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762-8. [Crossref]  [PubMed]  [PMC] 
  6. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021;191:4-17. [Crossref]  [PubMed]  [PMC] 
  7. Matsuyama T, Kubli SP, Yoshinaga SK, et al. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209-25. [Crossref]  [PubMed]  [PMC] 
  8. Eriksson O, Hultström M, Persson B, et al. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020;120:1720-4. [Crossref]  [PubMed]  [PMC] 
  9. Shrestha GS, Khanal S, Sharma S, et al. COVID-19: Current understanding of pathophysiology. J Nepal Health Res Counc. 2020;18:351-9. [Crossref]  [PubMed] 
  10. Dobesh PP, Trujillo TC. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy. 2020;40:1130-51. [Crossref]  [PubMed]  [PMC] 
  11. Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses. Curr Hypertens Rep. 2020;22:63. [Crossref]  [PubMed]  [PMC] 
  12. Santilli V, Bernetti A, Mangone M, et al. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014;11:177-80. [PubMed]  [PMC] 
  13. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021 Feb;9(3):e14726. [Crossref]  [PubMed]  [PMC] 
  14. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15: e0240784. [Crossref]  [PubMed]  [PMC] 
  15. Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020;26:1618-20. [Crossref]  [PubMed]  [PMC] 
  16. Goha A, Mezue K, Edwards P, et al. COVID-19 and the heart: An update for clinicians. Clin Cardiol. 2020;43:1216-22. [Crossref]  [PubMed]  [PMC] 
  17. Tsatsakis A, Calina D, Falzone L, et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 2020;146:111769. [Crossref]  [PubMed]  [PMC] 
  18. Silverio R, Gonçalves DC, Andrade MF, et al. Coronavirus Disease 2019 (COVID-19) and Nutritional Status: The Missing Link? Adv Nutr. 2021;12:682-92. [Crossref]  [PubMed]  [PMC] 
  19. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021;21:e63-e67. [Crossref]  [PubMed]  [PMC] 
  20. Mendelson M, Nel J, Blumberg L, et al. Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2020;111:10-12. [Link]  [PubMed] 
  21. Walsh-Messinger J, Manis H, Vrabec A, et al. The Kids Are Not Alright: A Preliminary Report of Post-COVID Syndrome in University Students. medRxiv [Preprint]. 2020:2020.11.24.2 0238261. [PubMed]  [PMC] 
  22. Garg RK. Spectrum of Neurological Manifestations in Covid-19: A Review. Neurol India. 2020;68:560-72. [Crossref]  [PubMed] 
  23. Kanwar D, Baig AM, Wasay M. Neurological manifestations of COVID-19. J Pak Med Assoc. 2020;70:S101-S103. [Crossref]  [PubMed] 
  24. Bobker SM, Robbins MS. COVID-19 and Headache: A Primer for Trainees. Headache. 2020;60:1806-11. [Crossref]  [PubMed]  [PMC] 
  25. Liu JWTW, de Luca RD, Mello Neto HO, et al. Post-COVID-19 Syndrome? New daily persistent headache in the aftermath of COVID-19. Arq Neuropsiquiatr. 2020;78:753-4. [Crossref]  [PubMed] 
  26. Garnero M, Del Sette M, Assini A, et al. COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. J Neurol Sci. 2020;418:117114. [Crossref]  [PubMed]  [PMC] 
  27. Betsch D, Freund PR. Neuro-ophthalmological manifestations of novel coronavirus. Adv Ophthalmol Optom. 2021. [PubMed]  [PMC] 
  28. Luís ME, Hipólito-Fernandes D, Mota C, et al. A Review of Neuro-Ophthalmological Manifestations of Human Coronavirus Infection. Eye Brain. 2020;12:129-37. [Crossref]  [PubMed]  [PMC] 
  29. Correia AO, Feitosa PWG, Moreira JLS, et al. Neurological manifestations of COVID-19 and other coronaviruses: A systematic review. Neurol Psychiatry Brain Res. 2020;37:27-32. [Crossref]  [PubMed]  [PMC] 
  30. Katyal N, Narula N, Acharya S, et al. Neuromuscular complications with SARS-COV-2 Infection: A Review. Front Neurol. 2020;11:1052. [Crossref]  [PubMed]  [PMC] 
  31. Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol. 2020;92:1743-4. [Crossref]  [PubMed]  [PMC] 
  32. Derksen RH, de Groot PG. Clinical consequences of antiphospholipid antibodies. Neth J Med. 2004;62:273-8. [PubMed] 
  33. Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost. 2020:10. 1111/jth.14893. [Crossref]  [PubMed]  [PMC] 
  34. Zuo Y, Estes SK, Gandhi AA, et al. Prothrombotic antiphospholipid antibodies in COVID-19. medRxiv [Preprint]. 2020:2020.06.15. 20131607. [PubMed]  [PMC] 
  35. Zaladonis A, Huang S, Hsu S. COVID toes or pernio? Clin Dermatol. 2020;38:764-7. [Crossref]  [PubMed]  [PMC] 
  36. Freeman EE, McMahon DE, Lipoff JB, et al; American Academy of Dermatology Ad Hoc Task Force on COVID-19. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83:486-92. [Crossref]  [PubMed]  [PMC] 
  37. Perrin R, Riste L, Hann M, et al. Into the looking glass: Post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055. [Crossref]  [PubMed]  [PMC] 
  38. George JM, Xu Y, Nursa'adah BJ, et al. Collaboration between a tertiary pain centre and community teams during the pandemic. Br J Community Nurs. 2020;25:480-8. [Crossref]  [PubMed] 
  39. Nijs J, Torres-Cueco R, van Wilgen CP, et al. Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization pain. Pain Physician. 2014; 17: 447-57. [Crossref]  [PubMed] 
  40. Neblett R, Hartzell MM, Williams M, et al. Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. Spine J. 2017;17:1819-29. [Crossref]  [PubMed] 
  41. Serrano-Ibá-ez ER, Esteve R, Ramírez-Maestre C, et al. Chronic pain in the time of COVID-19: Stress aftermath and central sensitization. Br J Health Psychol. 2021;26:544-52. [Crossref]  [PubMed] 
  42. Salaffi F, Giorgi V, Sirotti S, et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin Exp Rheumatol. 2021;39 Suppl 130:72-7. [PubMed] 
  43. Mohabbat AB, Mohabbat NML, Wight EC. Fibromyalgia and Chronic Fatigue Syndrome in the Age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4:764-6. [Crossref]  [PubMed]  [PMC] 
  44. Şahin T, Ayyildiz A, Gencer-Atalay K, et al. Pain symptoms in COVID-19. Am J Phys Med Rehabil. 2021;100:307-12. [Crossref]  [PubMed] 
  45. López-González MD, Peral-Garrido ML, Calabuig I, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis. 2020:annrheumdis-2020-217914. [PubMed] 
  46. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020;2: e655-e657. [Crossref]  [PubMed]  [PMC] 
  47. Berkovic D, Ackerman IN, Briggs AM, et al. Tweets by people with arthritis during the COVID-19 pandemic: Content and sentiment analysis. J Med Internet Res. 2020;22: e24 550. [Crossref]  [PubMed]  [PMC] 
  48. Jali I. Reactive arthritis after COVID-19 infection. Cureus. 2020;12:e11761. [Crossref]  [PubMed]  [PMC] 
  49. Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6:e001350. [Crossref]  [PubMed]  [PMC] 
  50. Sheehy LM. Considerations for postacute rehabilitation for survivors of COVID-19. JMIR Public Health Surveill. 2020;6:e19462. [Crossref]  [PubMed]  [PMC] 
Copyright © 2024
Bu sitenin tüm hakları Türkiye Fiziksel Tıp ve Rehabilitasyon Uzman Hekimleri Derneği'ne aittir.
Site Tasarım ve Yönetim: Türkiye Klinikleri